Patients Stopping Slimming Jabs Put On Weight Far More Rapidly Compared to People Using Diet and Exercise

A recent study indicates that individuals who discontinue new GLP-1 drugs like semaglutide or tirzepatide tend to recover shed pounds at a significantly accelerated pace than those who halt conventional lifestyle plans.

Research printed in a major health publication points out that while overweight individuals can lose substantial amounts of their total mass while on the medication, the weight returns at an estimated rate of 0.8 kg per month after stopping.

"Individuals using such medications should be aware of the risk of quick rebound weight gain when the treatment is stopped," cautioned expert Dr. Susan Jebb.

That rate of recovery suggests a reversion to pre-treatment weight in about 18 months.

Weighing Therapies

The analysis, which looked at 37 of trials involving over 9,000 of patients, compared the results of the injectable medications with other pills.

The team note that people who lose weight through lifestyle changes alone typically experience a less rapid weight regain—around 100 grams monthly—post-intervention.

Explaining the Fast Rebound

Nutrition scientists propose the mechanism of the jabs accounts for the amplified regain.

The injections copy a natural hormone called glucagon-like peptide-1, which moderates hunger.

"Long-term administration of GLP-1 levels far above than the body's typical production could lead to the body to generate a reduced amount of its own natural GLP-1, and could reduce responsiveness to its actions," explained Dr. Adam Collins, a dietetics researcher.

"Discontinuation of this medication means hunger is unsuppressed, making binge eating a significant risk."

A Lifelong Disease?

Health authorities suggest the injections for people with weight-linked health risks, accompanied by recommended lifestyle changes.

Professionals contend that, considering the significant potential of weight regain, the treatment should be considered life-long.

This perspective is reinforced by drug manufacturers, who say that the findings "emphasize the chronic character of obesity," comparing it to managing conditions like high blood pressure.

Patient Experiences

People who have discontinued the jabs describe a intense resurgence of cravings.

"It felt as if a trigger that goes on and you're instantly starving," described one woman.

The struggle is exacerbated if patients have not adopted sustainable lifestyle or habit changes during treatment.

Significant Interest

Figures indicate that millions of people in the UK have tried weight-loss jabs in the last 12 months, with demand being substantial.

• Adoption is more common among females compared to men.
• The 40s and 50s demographic shows the greatest usage rates.
• Many obtain the medications through private prescriptions rather than the NHS.

In conclusion, experts caution that while GLP-1 drugs are potent tools for shedding pounds, they are not a standalone fix and maintained weight loss hinges on ongoing lifestyle management.